Forest Laboratories, Inc. (Forest), develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD). In February 2014, it acquired Aptalis. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:FRX
- CUSIP: 34583810
- Web: N/A
- Trailing P/E Ratio: N/A
- P/E Growth: 0
Frequently Asked Questions for Forest Laboratories (NYSE:FRX)
What is Forest Laboratories' stock symbol?
Forest Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "FRX."
Who are some of Forest Laboratories' key competitors?
Some companies that are related to Forest Laboratories include Ampio Pharmaceuticals (AMPE), Pernix Therapeutics Holdings (PTX), Allergan plc (ACT), Auxilium Pharmaceuticals (AUXL), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), Hi-Tech Pharmacal (HITK), Optimer Pharmaceuticals (OPTR), Questcor Pharmaceuticals (QCOR), Salix Pharmaceuticals (SLXP), Santarus (SNTS), Shire Viropharma (VPHM) and Warner Chilcott Plc (WCRX).
How do I buy Forest Laboratories stock?
Shares of Forest Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Forest Laboratories stock cost?
One share of Forest Laboratories stock can currently be purchased for approximately $0.73.
Consensus Ratings for Forest Laboratories (NYSE:FRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Forest Laboratories (NYSE:FRX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Forest Laboratories (NYSE:FRX)Earnings History by Quarter for Forest Laboratories (NYSE:FRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/29/2014||Q414||$0.45||$0.87||$959.00 million||$1.05 million||View||N/A|
|1/21/2014||Q314||$0.06||$0.27||$827.25 million||$846.80 million||View||N/A|
|7/23/2013||Q1 2014||$0.09||$0.28||$798.41 million||$796.90 million||View||N/A|
|4/23/2013||Q4 2013||$0.16||$0.17||$807.00 million||$783.20 million||View||N/A|
|1/15/2013||Q3 2013||($0.14)||($0.21)||$765.94 million||$678.00 million||View||N/A|
Earnings Estimates for Forest Laboratories (NYSE:FRX)
Current Year EPS Consensus Estimate: $-0.20 EPS
Dividend History for Forest Laboratories (NYSE:FRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Forest Laboratories (NYSE:FRX)Insider Trades by Quarter for Forest Laboratories (NYSE:FRX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/27/2014||Howard Solomon||Director||Sell||250,000||$65.41||$16,352,500.00|| |
|1/23/2014||Howard Solomon||Director||Sell||250,000||$67.13||$16,782,500.00|| |
|1/22/2014||Jerome Lynch||SVP||Sell||135,625||$67.28||$9,124,850.00|| |
|8/26/2013||Lawrence Olanoff||Director||Sell||1,104||$42.96||$47,427.84|| |
|8/21/2013||Perier Francis, Jr.||CFO||Sell||12,000||$43.00||$516,000.00|| |
|9/4/2012||Carl C Icahn||Major Shareholder||Buy||86,848||$34.64||$3,008,414.72|| |
|8/29/2012||Carl C Icahn||Major Shareholder||Buy||331,406||$34.65||$11,483,217.90|| |
|8/24/2012||Carl C Icahn||Major Shareholder||Buy||1,343,837||$34.57||$46,456,445.09|| |
|8/21/2012||Carl C Icahn||Major Shareholder||Buy||1,962,011||$34.18||$67,061,535.98|| |
Headline Trends for Forest Laboratories (NYSE:FRX)
Latest Headlines for Forest Laboratories (NYSE:FRX)
Forest Laboratories (FRX) Chart for Saturday, May, 27, 2017